Back to Search
Start Over
OSE Immunotherapeutics presents the positive results of step 1 of phase 3 of Tedopi(r) in non-small cell lung cancer at the virtual congress ESMO 2020 (European Society for Medical Oncology)
- Source :
- Plus Company Updates. September 22, 2020
- Publication Year :
- 2020
-
Abstract
- Amsterdam: OSE IMMUNE has issued the following news release: OSE Immunotherapeutics SA (Paris: OSE) (ISIN: FR0012127173; Mnemo: OSE), presented the positive results of step 1 of phase 3 of the [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.636366125